CSTL Castle Biosciences

Castle Biosciences Honored with Multiple Top Workplaces Awards Recognizing the Company’s Strong Culture

Castle Biosciences Honored with Multiple Top Workplaces Awards Recognizing the Company’s Strong Culture

Castle earns recognition as a national Healthcare Industry Top Workplace, an Arizona Top Workplace and receives five Top Workplaces Culture Excellence awards

FRIENDSWOOD, Texas, July 17, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has earned multiple awards through the 2025 Top Workplaces program: a third consecutive national Healthcare Industry Top Workplaces award, with Castle ranking third among other recognized companies in its size bracket; a fourth consecutive regional Arizona Top Workplaces award from AZ Central; and consecutive national Top Workplaces Culture Excellence awards for Innovation, Work-Life Flexibility, Compensation & Benefits, Leadership and Purpose & Values.

“Being recognized as a Top Workplace, year after year, demonstrates the incredible strength of our Castle team and commitment to our shared mission to improve health through innovative tests that guide patient care,” said Derek Maetzold, president and chief executive officer of Castle Biosciences. “These employee-driven honors affirm that our people-first culture isn't just a philosophy, but a catalyst that helps fuel our innovation and impact.”

Top Workplaces awards recognize organizations that have built exceptional workplace cultures, with regional and industry awards celebrating employers of choice within specific areas, and culture excellence awards highlighting organizations that excel in particular aspects of workplace culture. Award designations are garnered solely through anonymous employee feedback gathered through a third-party survey administered by Energage. The confidential survey measures the workplace experience and various culture themes that are indicative of successful organizations, such as employees feeling “fairly valued,” “engaged,” and “respected and supported.”

Castle’s receipt of the Top Workplaces Culture Excellence awards listed below underscores its strong, people-first culture and provides distinction in the following areas:

  • Innovation (2022-2025), for embedding innovation into its culture and creating an environment where new ideas come from all employees.
  • Work-Life Flexibility (2023-2025), for building a culture that enables employees to meet the demands of their personal lives while maintaining high performance.
  • Compensation & Benefits (2022-2025), for providing employees not only with material rewards but also with appreciation for their work.
  • Leadership (2022-2025), for organizational leaders who inspire confidence in their employees and in the direction of the company.
  • Purpose & Values (2022-2025), for successfully communicating the company mission and integrating those aspirations into the culture.



About Castle Biosciences

Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.

Castle’s current portfolio consists of tests for skin cancers, Barrett’s esophagus and uveal melanoma. Additionally, the Company has active research and development programs for tests in these and other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis seeking biologic treatment. To learn more, please visit  and connect with us on , ,  and . 

DecisionDx-Melanoma, DecisionDx-CMSeq, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, TissueCypher, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.

Investor Contact:

Camilla Zuckero

Media Contact:

Allison Marshall



EN
17/07/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Castle Biosciences

 PRESS RELEASE

Castle Biosciences Honored with Multiple Top Workplaces Awards Recogni...

Castle Biosciences Honored with Multiple Top Workplaces Awards Recognizing the Company’s Strong Culture Castle earns recognition as a national Healthcare Industry Top Workplace, an Arizona Top Workplace and receives five Top Workplaces Culture Excellence awards FRIENDSWOOD, Texas, July 17, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has earned multiple awards through the 2025 Top Workplaces program: a third consecutive national Healthcare Industry Top Workplaces aw...

 PRESS RELEASE

Castle Biosciences to Release Second Quarter 2025 Financial Results an...

Castle Biosciences to Release Second Quarter 2025 Financial Results and Host Conference Call on Monday, Aug. 4, 2025 FRIENDSWOOD, Texas, July 14, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the second quarter ended June 30, 2025, after the close of market on Monday, Aug. 4, 2025. Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day. Conference Call...

 PRESS RELEASE

Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule...

Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) FRIENDSWOOD, Texas, June 19, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that on June 14, 2025, the Compensation Committee of its Board of Directors granted restricted stock units (RSUs) to 66 employees covering an aggregate of 135,978 shares of common stock as an inducement material to their entering into employment with Castle Biosciences. The RSUs were granted pursuant to the Company’s 2022 I...

 PRESS RELEASE

Castle Biosciences Enters Collaboration and License Agreement with Sci...

Castle Biosciences Enters Collaboration and License Agreement with SciBase to Develop Diagnostic Tests for Dermatologic Diseases Initial Development Project Targets Predicting Flares in Patients Diagnosed with Atopic Dermatitis FRIENDSWOOD, Texas, June 16, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has entered into a collaboration and license agreement with SciBase Holding AB (“SciBase”) utilizing SciBase’s Electrical Impedance Spectroscopy technology which include...

 PRESS RELEASE

Castle Biosciences’ Chief Executive Officer Derek Maetzold to Particip...

Castle Biosciences’ Chief Executive Officer Derek Maetzold to Participate in Panel Discussion During the 2025 BIO International Convention FRIENDSWOOD, Texas, June 11, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that Derek Maetzold, founder, president and chief executive officer of Castle Biosciences, will participate in a panel discussion alongside other industry leaders during the 2025 BIO International Convention (BIO 2025), being held June 16-19 in Boston. The panel will ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch